nach oben

Pathology & Oncology Research

Erschienen in:

01.12.2010

CD24 and Galectin-1 Expressions in Gastric Adenocarcinoma and Clinicopathologic Significance

verfasst von: Sibel Bektas, Burak Bahadir, Bulent Hamdi Ucan, Sukru Oguz Ozdamar

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

CD24 and galectin-1 expression in gastric adenocarcinoma and their clinicopathologic significance remained largely unknown. We aimed to evaluate expressions and staining intensities of CD24 and galectin-1 in gastric adenocarcinoma and to investigate the interrelation with clinicopathologic parameters including survival. 93 cases with gastric adenocarcinoma were reevaluated histopathologically and immunohistochemistry was performed with antibodies against CD24 and galectin-1. Staining intensities of both markers in tumor cells and staining intensity of galectin-1 in tumor-associated stromal cells were scored semiquantitatively. The relationship between expression and staining intensity of CD24 and galectin-1 and clinicopathologic variables were assessed. CD24 staining intensity was associated with lymphovascular invasion (p = 0.007), serosal invasion (p = 0.001), stage (p = 0.001) and lymph node metastasis (p = 0.005). Galectin-1 staining intensity in tumor-associated stromal cells was associated with tumor location (p = 0.031), lymphovascular invasion (p = 0.001), perineural invasion (p = 0.001), serosal invasion (p = 0.001), differentiation (p = 0.003), stage (p = 0.001) and lymph node metastasis (p = 0.001). Staining intensity of CD24 (p = 0.019) and gal-1 (p = 0.018) were associated with patient survival. Staining intensity of CD24 in tumor cells and galectin-1 in tumor-associated stromal cells were related with certain clinicopathologic variables. Our findings suggest that these markers are independent prognostic indicators of poor survival and may serve as useful targets for novel therapies.

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMed

Rosai J (2004) Stomach. In: Rosai J (ed) Rosai and Ackerman’s surgical pathology, 9th edn. Elsevier-Mosby, New York, pp 648–684

Chou YY, Jeng YM, Lee TT et al (2007) Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 14:2748–2758CrossRefPubMed

Lim SC, Oh SH (2005) The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 201:479–486CrossRefPubMed

Baumann P, Cremers N, Kroese F et al (2005) CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65:10783–10793CrossRefPubMed

Li O, Zheng P, Liu Y (2004) CD24 expression on T cells is required for optimal T cell proliferation in lymphopenic host. J Exp Med 200:1083–1089CrossRefPubMed

Nielsen PJ, Lorenz B, Müller AM et al (1997) Altered erythrocytes and a leaky block in B-cell development in CD24/HSA-deficient mice. Blood 89:1058–1067PubMed

Aigner S, Sthoeger ZM, Fogel M et al (1997) CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89:3385–3395PubMed

Athanassiadou P, Grapsa D, Gonidi M et al (2009) CD24 expression has a prognostic impact in breast carcinoma. Pathol Res Pract 205:524–533CrossRefPubMed

10.

Kristiansen G, Winzer KJ, Mayordomo E et al (2003) CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9:4906–4913PubMed

11.

Kristiansen G, Denkert C, Schlüns K et al (2002) CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161:1215–1221PubMed

12.

Lee HJ, Kim DI, Kwak C et al (2008) Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology 72:603–607CrossRefPubMed

13.

Kristiansen G, Pilarsky C, Pervan J et al (2004) CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 58:183–192CrossRefPubMed

14.

Sano A, Kato H, Sakurai S et al (2009) CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 16:506–514CrossRefPubMed

15.

Kristiansen G, Schlüns K, Yongwei Y et al (2003) CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 88:231–236CrossRefPubMed

16.

Georgiadis V, Stewart HJ, Pollard HJ et al (2007) Lack of galectin-1 results in defects in myoblast fusion and muscle regeneration. Dev Dyn 236:1014–1024CrossRefPubMed

17.

Hsu DK, Liu FT (2004) Regulation of cellular homeostasis by galectins. Glycoconj J 19:507–515CrossRefPubMed

18.

Hittelet A, Legendre H, Nagy N et al (2003) Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 103:370–379CrossRefPubMed

19.

Sakaguchi M, Imaizumi Y, Okano H (2007) Expression and function of galectin-1 in adult neural stem cells. Cell Mol Life Sci 64:1254–1258CrossRefPubMed

20.

Satelli A, Rao PS, Gupta PK et al (2008) Varied expression and localization of multiple galectins in different cancer cell lines. Oncol Rep 19:587–594PubMed

21.

Thijssen VL, Hulsmans S, Griffioen AW (2008) The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 172:545–553CrossRefPubMed

22.

Jung EJ, Moon HG, Cho BI et al (2007) Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 120:2331–2338CrossRefPubMed

23.

Clausse N, van den Brûle F, Waltregny D et al (1999) Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell–cell adhesion. Angiogenesis 3:317–325CrossRefPubMed

24.

Nagy N, Legendre H, Engels O et al (2003) Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 97:1849–1858CrossRefPubMed

25.

Kristiansen G, Sammar M, Altevogt P (2004) Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35:255–262CrossRefPubMed

26.

Lim SC (2005) CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 59:S351–354CrossRefPubMed

27.

van den Brûle F, Califice S, Castronovo V (2004) Expression of galectins in cancer: a critical review. Glycoconj J 19:537–542CrossRefPubMed

28.

Camby I, Le Mercier M, Lefranc F et al (2006) Galectin-1: a small protein with major functions. Glycobiology 16:137R–157RCrossRefPubMed

29.

Fogel M, Friederichs J, Zeller Y et al (1999) CD24 is a marker for human breast carcinoma. Cancer Lett 143:87–94CrossRefPubMed

30.

Bircan S, Kapucuoglu N, Baspinar S et al (2006) CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 202:569–576CrossRefPubMed

31.

Weichert W, Denkert C, Burkhardt M et al (2005) Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 11:6574–6581CrossRefPubMed

32.

Sagiv E, Arber N (2008) The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy. Expert Rev Gastroenterol Hepatol 2:125–133CrossRefPubMed

33.

Nagy B, Szendroi A, Romics I (2009) Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. Pathol Oncol Res 15:279–283CrossRefPubMed

34.

Huang LR, Hsu HC (1995) Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 55:4717–4721PubMed

35.

Kim KH, Choi JS, Kim JM et al (2009) Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium. Histol Histopathol 24:309–316PubMed

36.

Kim JB, Ko E, Han W et al (2008) CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer 24:118CrossRef

37.

Agrawal S, Kuvshinoff BW, Khoury T et al (2007) CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg 11:445–451CrossRefPubMed

38.

Chiariotti L, Berlingieri MT, Battaglia C et al (1995) Expression of galectin-1 in normal human tyroid gland and in differentiated and poorly differentiated tyroid tumors. Int J Cancer 64:171–175CrossRefPubMed

39.

van den Brule F, Califice S, Garnier F et al (2003) Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab Invest 83:377–386PubMed

40.

Shimonishi T, Miyazaki K, Kano N et al (2001) Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32:302–310CrossRefPubMed

41.

Berberat PO, Friess H, Wang L et al (2001) Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 49:539–549PubMed

42.

Cindolo L, Benvenuto G, Salvatore G et al (1999) Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinoma. Int J Cancer 84:39–43CrossRefPubMed

43.

Cooper DN, Barondes SH (1990) Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism. J Cell Biol 110:1681–1691CrossRefPubMed

44.

van den Brule F, Waltregny D, Castronovo V (2001) Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinomapatients. J Pathol 193:80–87CrossRefPubMed

45.

Zhu XL, Liang L, Ding YQ (2007) Galectin-1 expression in human colorectal carcinoma and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao 27:1331–1334PubMed

46.

Le QT, Shi G, Cao H et al (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23:8932–8941CrossRefPubMed

47.

Rorive S, Belot N, Decaestecker C et al (2001) Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 33:241–255CrossRefPubMed

Titel: CD24 and Galectin-1 Expressions in Gastric Adenocarcinoma and Clinicopathologic Significance
verfasst von: Sibel Bektas
Burak Bahadir
Bulent Hamdi Ucan
Sukru Oguz Ozdamar
Publikationsdatum: 01.12.2010
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 4/2010
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-010-9248-8

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

CD24 and Galectin-1 Expressions in Gastric Adenocarcinoma and Clinicopathologic Significance

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Genetic Polymorphisms of Paraoxonase 1 (PON1) Gene: Association Between L55M or Q192R with Breast Cancer Risk and Clinico-Pathological Parameters

Minute Myopericytoma of the Neck: A Case Report with Literature Review and Differential Diagnosis

Overexpression of Cortactin Increases Invasion Potential in Oral Squamous Cell Carcinoma

R72P Polymorphism of TP53 in Ulcerative Colitis Patients is Associated with the Incidence of Colectomy, Use of Steroids and the Presence of a Positive Family History

Wild Type p53 Gene Sensitizes Rat C6 Glioma Cells to HSV-TK/ACV Treatment In Vitro and In Vivo

Nuclear Grading Versus Gleason Grading in Small Samples Containing Prostate Cancer: A Tissue Microarray Study

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie